IP Library › Granted Patent US 10,752,689
Granted Patent B2
US 10,752,689 · App. 16/019,011 · Granted Aug 25, 2020

Hybridoma clones, monoclonal antibodies to VSIG-4, and methods of making and using

Inventors: Birte Aggeler (Minneapolis, MN); Christine Goetz (Blaine, MN); Jody Bonnevier (Chanhassen, MN); Christopher Carlin Valley (Minnetonka, MN); Chris Hammerbeck (Shoreview, MN); Ernesto Ruben Resnik (Minneapolis, MN)
Assignee: BIO-TECHNE CORPORATION
C07K16/2854A61K31/573A61P35/00A61P37/06C07K16/2803C12N5/163C07K2317/76C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,752,689
App. No.
16/019,011
Granted
Aug 25, 2020
Kind
B2
Abstract

Described herein are monoclonal antibodies that bind to VSIG-4 including antibodies that block the binding of VSIG-4 to SIGLEC-7, compositions including the monoclonal antibodies, and methods of making and using those antibodies and compositions.

Claims (42)

1. A monoclonal antibody produced by at least one of the following clones:

Ms×hVSIG4 528902.11 (ATCC Accession No. PTA-124187);

Ms×hVSIG4 528903.111 (ATCC Accession No. PTA-124188);

Ms×hVSIG4 528905.11 (ATCC Accession No. PTA-124189);

Ms×hVSIG4 528906.11 (ATCC Accession No. PTA-124178);

Ms×hVSIG4 528908.11 (ATCC Accession No. PTA-124179);

Ms×hVSIG4 528910.111 (ATCC Accession No. PTA-124180);

Ms×hVSIG4 528912.11 (ATCC Accession No. PTA-124181);

Ms×hVSIG4 528922.111 (ATCC Accession No. PTA-124182);

Ms×hVSIG4 528927.111 (ATCC Accession No. PTA-124183);

Rt×hVSIG4 489509.11 (ATCC Accession No. PTA-124184);

Rt×hVSIG4 489517.111 (ATCC Accession No. PTA-124185); and

Rt×hVSIG4 489518.11 (ATCC Accession No. PTA-124186).

2. The monoclonal antibody of claim 1 , wherein the antibody binds to VSIG-4.

3. A monoclonal antibody, wherein the monoclonal antibody comprises:

a heavy chain variable region comprising the three complementarity determining regions (CDRs) of the heavy chain of a monoclonal antibody produced by Ms×hVSIG4 528902.11 (ATCC Accession No. PTA-124187), and a light chain variable region comprising the three CDRs of the light chain of a monoclonal antibody produced by Ms×hVSIG4 528902.11 (ATCC Accession No. PTA-124187);

a heavy chain variable region comprising the three CDRs of the heavy chain of a monoclonal antibody produced by Ms×hVSIG4 528903.111 (ATCC Accession No. PTA-124188), and a light chain variable region comprising the three CDRs of the light chain of a monoclonal antibody produced by Ms×hVSIG4 528903.111 (ATCC Accession No. PTA-124188);

a heavy chain variable region comprising the three CDRs of the heavy chain of a monoclonal antibody produced by Ms×hVSIG4 528905.11 (ATCC Accession No. PTA-124189), and a light chain variable region comprising the three CDRs of the light chain of a monoclonal antibody produced by Ms×hVSIG4 528905.11 (ATCC Accession No. PTA-124189);

a heavy chain variable region comprising the three CDRs of the heavy chain of a monoclonal antibody produced by Ms×hVSIG4 528906.11 (ATCC Accession No. PTA-124178), and a light chain variable region comprising the three CDRs of the light chain of a monoclonal antibody produced by Ms×hVSIG4 528906.11 (ATCC Accession No. PTA-124178);

a heavy chain variable region comprising the three CDRs of the heavy chain of a monoclonal antibody produced by Ms×hVSIG4 528908.11 (ATCC Accession No. PTA-124179), and a light chain variable region comprising the three CDRs of the light chain of a monoclonal antibody produced by Ms×hVSIG4 528908.11 (ATCC Accession No. PTA-124179);

a heavy chain variable region comprising the three CDRs of the heavy chain of a monoclonal antibody produced by Ms×hVSIG4 528910.111 (ATCC Accession No. PTA-124180), and a light chain variable region comprising the three CDRs of the light chain of a monoclonal antibody produced by Ms×hVSIG4 528910.111 (ATCC Accession No. PTA-124180);

a heavy chain variable region comprising the three CDRs of the heavy chain of a monoclonal antibody produced by Ms×hVSIG4 528912.11 (ATCC Accession No. PTA-124181), and a light chain variable region comprising the three CDRs of the light chain of a monoclonal antibody produced by Ms×hVSIG4 528912.11 (ATCC Accession No. PTA-124181);

a heavy chain variable region comprising the three CDRs of the heavy chain of a monoclonal antibody produced by Ms×hVSIG4 528922.111 (ATCC Accession No. PTA-124182), and a light chain variable region comprising the three CDRs of the light chain of a monoclonal antibody produced by Ms×hVSIG4 528922.111 (ATCC Accession No. PTA-124182);

a heavy chain variable region comprising the three CDRs of the heavy chain of a monoclonal antibody produced by Ms×hVSIG4 528927.111 (ATCC Accession No. PTA-124183), and a light chain variable region comprising the three CDRs of the light chain of a monoclonal antibody produced by Ms×hVSIG4 528927.111 (ATCC Accession No. PTA-124183);

a heavy chain variable region comprising the three CDRs of the heavy chain of a monoclonal antibody produced by Rt×hVSIG4 489509.11 (ATCC Accession No. PTA-124184), and a light chain variable region comprising the three CDRs of the light chain of a monoclonal antibody produced by Rt×hVSIG4 489509.11 (ATCC Accession No. PTA-124184);

a heavy chain variable region comprising the three CDRs of the heavy chain of a monoclonal antibody produced by Rt×hVSIG4 489517.111 (ATCC Accession No. PTA-124185), and a light chain variable region comprising the three CDRs of the light chain of a monoclonal antibody produced by Rt×hVSIG4 489517.111 (ATCC Accession No. PTA-124185); or

a heavy chain variable region comprising the three CDRs of the heavy chain of a monoclonal antibody produced by Rt×hVSIG4 489518.11 (ATCC Accession No. PTA-124186), and a light chain variable region comprising the three CDRs of the light chain of a monoclonal antibody produced by Rt×hVSIG4 489518.11 (ATCC Accession No. PTA-124186).

4. The monoclonal antibody of claim 3 , wherein the antibody binds to VSIG-4.

5. The monoclonal antibody of claim 4 , wherein the monoclonal antibody abrogates the binding of VSIG-4 to SIGLEC-7.

6. The monoclonal antibody of claim 5 , wherein VSIG-4 or SIGLEC-7 or both are on a cell surface.

7. The monoclonal antibody of claim 5 , wherein VSIG-4 is on the surface of an M2c macrophage.

8. The monoclonal antibody of claim 5 , wherein the monoclonal antibody abrogates a cell-cell interaction.

9. The monoclonal antibody of claim 4 , wherein the monoclonal antibody binds to an extracellular domain of VSIG-4.

10. The monoclonal antibody of claim 4 , wherein the monoclonal antibody binds to a VSIG-4 polypeptide.

11. The monoclonal antibody of claim 4 , wherein the monoclonal antibody binds to glycosylated and unglycosylated VSIG-4.

12. The monoclonal antibody of claim 4 , wherein the monoclonal antibody is coupled directly or indirectly to a detectable marker.

13. The monoclonal antibody of claim 4 , wherein the monoclonal antibody comprises an IgG antibody.

14. The monoclonal antibody of claim 4 , wherein the monoclonal antibody comprises an antigen-binding fragment comprising at least one of a Fab fragment, a Fab′ fragment, a F(ab) 2 fragment, and a FIT fragment.

15. A composition comprising the monoclonal antibody of claim 4 .

16. A kit comprising the monoclonal antibody of claim 4 .

17. The monoclonal antibody of claim 4 , wherein VSIG-4 is on the surface of an M2c macrophage.

18. The monoclonal antibody of claim 4 , wherein the monoclonal antibody abrogates a cell-cell interaction.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 30, 2019
From: RESNIK, ERNESTO RUBEN
To: BIO-TECHNE CORPORATION
Reel/Frame 049036/0682 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 22, 2018
From: AGGELER, BIRTE; GOETZ, CHRISTINE; BONNEVIER, JODY; VALLEY, CHRISTOPHER CARLIN; HAMMERBECK, CHRIS
To: BIO-TECHNE CORPORATION
Reel/Frame 046660/0444 →
Continuity (2)
Provisional Application 62524821 · Jun 26, 2017
Related Publication 20180371095A1 · Dec 27, 2018
Cited By (2)
US 12,196,754 US 12,383,893